SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
CAMBRIDGE, Mass., Feb. 28, 2017 -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Richard Murray, Ph.D., chief executive officer of Jounce, will present a company overview at the Cowen and Company 37th Annual Health Care Conference at 10:40 a.m. E.T. on Tuesday, March 7, 2017 in Boston.
A live webcast of the presentation will be available by visiting the Investors and Media section of Jounce’s website at http://ir.jouncetx.com. A replay of the webcast will be archived for 30 days following the presentation.
About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in a Phase 1/2 trial. For more information, please visit http://jouncetx.com/.
Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact: Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 [email protected]
